[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.202.12. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 1956

Treatment of Chronic Granulocytic Leukemia with Myleran

Author Affiliations

Chicago

From the Hematology Section of the Department of Medicine, University of Illinois, College of Medicine. Technical assistance was given by Adelle M. Frost.

AMA Arch Intern Med. 1956;97(3):299-308. doi:10.1001/archinte.1956.00250210045003
Abstract

In the hope of finding a less toxic analogue of nitrogen mustard, Haddow replaced the methyl groups in the nitrogen mustard molecule with various aromatic radicals. The compounds which were synthesized were not as effective as nitrogen mustard. Since the effect of nitrogen mustards is thought to be related to its ability to alkylate (i. e., exchange its halogen radical for some unknown body constituent), Timmis substituted another alkylating radical, sulfonic acid ester, for the halogen group. He synthesized a series of disulfonic ester molecules having various carbon chains. The four and five carbon chains were found to be most effective against the Walker rat carcinoma 256.1

Galton first reported the effects of 1,4-bis (methylsulfonoxy) butane (Myleran) in human leukemia.* After two years of experience in 19 patients with chronic granulo- cytic leukemia he reported clinical improvement similar to that obtained with x-ray therapy. Myleran was not found to

First Page Preview View Large
First page PDF preview
First page PDF preview
×